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Low-grade inflammation in adipose tissue and liver has been implicated in
obesity-associated insulin resistance and type 2 diabetes. Yet, the contribution of
inflammatory cells to the pathogenesis of skeletal muscle insulin resistance
remains elusive. In a large cohort of obese human individuals, blood monocyte
Fas (CD95) expression correlated with systemic and skeletal muscle insulin
resistance. To test a causal role for myeloid cell Fas expression in the
development of skeletal muscle insulin resistance, we generated myeloid/
haematopoietic cell-specific Fas-depleted mice. Myeloid/haematopoietic Fas
deficiency prevented the development of glucose intolerance in high fat-fed
mice, in ob/ob mice, and in mice acutely challenged by LPS. In vivo, ex vivo and
in vitro studies demonstrated preservation of muscle insulin responsiveness with
no effect on adipose tissue or liver. Studies using neutralizing antibodies
demonstrated a role for TNFa as mediator between myeloid Fas and skeletal
muscle insulin resistance, supported by significant correlations between
monocyte Fas expression and circulating TNFa in humans. In conclusion, our
results demonstrate an unanticipated crosstalk between myeloid cells and
skeletal muscle in the development of obesity-associated insulin resistance.
INTRODUCTION
Obese people are prone to type 2 diabetes, arising from relative
insulin deﬁciency combined with insulin resistance. The latter is
deﬁned as impaired ability of insulin to promote glucose uptake
into skeletal muscle and adipose tissue as well as to inhibit
hepatic glucose production. Since skeletal muscle is the
predominant site of insulin‐mediated glucose disposal in the
postprandial state (DeFronzo & Tripathy, 2009), development of
muscular insulin resistance will crucially impact on glucose
homeostasis. In fact, skeletal muscle insulin resistance is an early
metabolic alteration that frequently precedes type 2 diabetes
(DeFronzo & Tripathy, 2009). In obesity, low‐grade inﬂamma-
tion frequently develops systemically and in different organs
such as adipose tissue, liver or pancreatic islets, and is thought to
play a causative role in the pathogenesis of insulin resistance and
type 2 diabetes (Donath & Shoelson, 2011; Lazar, 2005;Weisberg
et al, 2003; Xu et al, 2003; Yuan et al, 2001). It is characterized by
elevated levels of pro‐inﬂammatory cytokines, and by inﬁltration
of these tissues with macrophages and other immune cells
(Nishimura et al, 2009; Weisberg et al, 2003; Winer et al,
2009, 2011; Xu et al, 2003). Moreover, although macrophage
accumulation was mainly studied in adipose tissue, skeletal
muscle may also be inﬁltrated, a process proposed to contribute
to high fat diet (HFD) induced insulin resistance (Olefsky &
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Glass, 2010). However, the contribution of inﬂammatory cells
including monocytes and macrophages to skeletal muscle
insulin resistance remains poorly understood (Mauer et al,
2010; Samokhvalov et al, 2009).
Fas–FasL interaction is regarded as an important action in
immune responses. Besides its well‐characterized role in the
induction of programmed cell death (apoptosis), there is
evidence that Fas activation may induce non‐apoptotic signalling
pathways such as inﬂammatory cascades (Guo et al, 2005; Peter
et al, 2007; Schumann et al, 2007; Wajant et al, 2003).
Accordingly, activation of the Fas signalling pathway was shown
to induce secretion of pro‐inﬂammatory cytokines like IL‐1a, IL‐
1b, IL‐6, IL‐8 (keratinocyte chemoattractant (KC)), MCP‐1 and
TNFa in different cell types such as adipocytes and monocytes
(Faouzi et al, 2001; Farley et al, 2008; Imamura et al, 2004; Miwa
et al, 1998; Park et al, 2003; Schaub et al, 2003; Wang et al, 2010;
Wueest et al, 2010b), rendering it a potential key component of
the inﬂammatory response. We previously found that Fas
ablation speciﬁcally in adipocytes reduced adipose tissue
inﬂammation and hepatic insulin resistance in high fat‐fed mice,
highlighting a role for Fas in the disturbed adipocyte–hepatocyte
communication observed in obesity (Wueest et al, 2010b).
In the present study, we hypothesized that myeloid cell‐
expressed Fas impacts on inﬂammatory pathways and, conse-
quently, on glucose homeostasis. To test this hypothesis,
monocytic Fas expression was analysed in a large cohort of
obese human individuals (n¼ 246) and correlated with the
parameters insulin sensitivity and glucose metabolism. In
addition, glucose metabolism was determined in standard
chow‐fed, HFD‐fed or LPS‐injected control and myeloid cell‐
speciﬁc Fas‐depleted mice on a C57BL6/J or ob/ob background.
Our results propose a thus far unknown Fas‐mediated crosstalk
between myeloid cells and skeletal muscle contributing to the
development of obesity‐associated insulin resistance.
RESULTS
Fas expression in circulating monocytes correlates with insulin
resistance and type 2 diabetes in obese patients
To unravel whether obesity has an impact on myeloid Fas
expression, mRNA levels were determined in circulating
monocytes of lean and obese human subjects (body mass index
(BMI): 21.4 0.5 kg/m2 in lean vs. 45.9 1.1 kg/m2 in obese
subjects, p< 0.0001). Intriguingly, Fas expression was signiﬁ-
cantly increased in obese compared to lean subjects (Fig 1A). To
further determine if Fas expression in circulating monocytes
signiﬁes a more metabolically morbid sub‐phenotype of human
lean obese
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Figure 1. Fas expression in circulating monocytes correlates negatively with insulin sensitivity in obese patients.
A. Monocytes were isolated fromwhole human blood samples of lean and obese subjects and FasmRNA expression wasmeasured normalized to HPRT. n¼16–
247. p¼0.005 (Student’s t-test). Error bars represent SEM.
B. Monocytes were isolated from whole human blood samples and Fas mRNA expression was measured normalized to HPRT. p<0.0001 (Student’s t-test).
NGT: normal glucose tolerance (men n¼61; women n¼70); T2D: type 2 diabetes (men n¼57; women n¼58). Error bars represent SEM.
C,D. Monocyte Fas mRNA expression was determined as described above and correlated to HOMA-IR (C) and glucose disposal rate (GDR) (D). n¼200 (C) and
n¼163 (D). Error bars represent SEM.
E. Monocyte Fas mRNA expression was determined in obese patients before and 6 months after bariatric surgery (gastric sleeve resection; n¼14),
p¼0.0002 (Student’s t-test).
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obesity, monocytic FasmRNA expression was analysed in obese
humans with either normal glucose tolerance (NGT; n¼ 131) or
with type 2 diabetes (n¼ 115). Basic clinical characteristics of
these subjects are provided in Table 1. Fas expression was not
different betweenmales and females, but higher in monocytes of
obese persons with type 2 diabetes compared to obese, normal
glucose tolerant subjects (Fig 1B). Similar to Fas, Fas ligand
(FasL) expression was increased in obese persons with type 2
diabetes (Supporting Information Fig 1). Strikingly, Fas expres-
sion in human circulating monocytes positively correlated with
HOMA‐IR (Fig 1C), a measure of systemic insulin resistance. To
gain more insight into potential mechanisms linking monocytic
Fas expression and insulin resistance, hyperinsulinaemic‐
euglycaemic clamp studies were performed. Fas mRNA in
circulating monocytes correlated negatively with glucose
disposal rate (GDR), a measure mainly reﬂecting skeletal muscle
insulin sensitivity (Fig 1D). Complementary to the cross‐sectional
study, surgery‐induced weight loss, which resulted in signiﬁ-
cantly improved insulin sensitivity (Supporting Information Fig
2), also resulted in a signiﬁcant decline in monocyte Fas mRNA
expression (Fig 1E). Clinical characteristics of these subjects are
provided in Table 1. Importantly, HOMA‐IR correlated with
monocyte Fas expression at baseline in the bariatric surgery
group (Supporting Information Fig 3) and changes in HOMA‐IR
6 months after bariatric surgery signiﬁcantly correlated with
changes in monocyte Fas mRNA expression, even after
adjustment for changes in BMI (r¼ 0.14, adjusted p¼ 0.042).
Jointly, these cross‐sectional and longitudinal associations
between monocyte‐expressed Fas and insulin resistance inspired
us to hypothesize that monocyte Fas plays a causal role in
obesity‐associated skeletal muscle insulin resistance. To test this
hypothesis, we generated myeloid‐speciﬁc Fas‐knockout mice.
Myeloid cell‐speciﬁc Fas deletion protects from HFD‐induced
muscle insulin resistance
In wild‐type mice, HFD‐induced obesity was associated with
elevated Fas levels in circulating monocytes as determined by
ﬂow cytometric analysis (Fig 2A and Supporting Information
Fig 4). In contrast, HFD did neither increase Fas levels in B‐ and
T‐lymphocytes nor in neutrophils (Supporting Information
Fig 5). In order to further assess a role for myeloid‐expressed
Fas in the development of obesity‐associated insulin resistance,
myeloid‐speciﬁc Fas‐knockout mice (Fasf/f, LysM‐Creþ/;
FasDmye) were generated using the cre‐lox system (Clausen
et al, 1999; Olefsky & Glass, 2010). LysM‐Cre mice allow speciﬁc
and highly efﬁcient deletion of loxP‐ﬂanked target genes in
myeloid cells, i.e. macrophages, monocytes, neutrophil gran-
ulocytes and partially dendritic cells (Clausen et al, 1999). As
controls, littermate mice with ﬂoxed Fas but absent Cre‐
recombinase (Cre) expression were used (Fasf/f, LysM‐Cre/;
FasF/F). Flow cytometric analysis revealed diminished Fas
protein levels in circulating monocytes and neutrophils of
FasDmye mice (Fig 2B and C). However, no reduction was
observed in non‐myeloid B‐ and T‐lymphocytes (Supporting
Information Fig 6A). Western blot analysis conﬁrmed reduced
Fas protein content in isolated macrophages of FasDmye mice
whereas it was unchanged in white adipose tissue, liver and
other tissues (Supporting Information Fig 6B). To investigate the
functional signiﬁcance of myeloid‐speciﬁc Fas‐deletion, FasDmye
mice were fed a standard chow or HFD for 6 weeks. Total
body weight gain was similar in FasDmye and their Cre‐negative
littermates under both diets (Fig 2D), and no signiﬁcant
differences were observed in either fat pad weights or adipocyte
size distribution (Supporting Information Fig 7A–C). Moreover,
FasL expression in myeloid cells was similar between both
genotypes upon HFD (Supporting Information Fig 8). Strikingly,
whereas 6 weeks of HFD impaired glucose and insulin tolerance
tests in FasF/F compared to chow‐fed mice, FasDmye mice showed
no deterioration in glucose metabolism (Fig 2E and F). In
addition, fasting blood glucose levels were signiﬁcantly lower
in HFD‐fed FasDmye compared to FasF/F littermates, whereas
insulin, free fatty acid (FFA) and triglyceride (TG) levels as well
as circulating adiponectin and leptin levels did not differ
signiﬁcantly between the two genotypes (Table 2). The
protective effect against HFD‐induced glucose and insulin
intolerance by myeloid cell‐speciﬁc Fas deletion could not be
Table 1. Basic clinical characteristics of patients
Cross‐sectional study Bariatric surgery intervention
NGT T2D Baseline 6 Months post
Age 41.314.6 51.913 41.913.3
Gender (M/F) 61/70 57/58 4/10
BMI (kg/m2) 40.211.7 47.710.8 54.18.1 36.37.3b
Body fat (%) 37.211.9 42.110.2 56.18.3 38.57.2b
HbA1c (%) 5.70.3 7.11.0a 6.60.9 5.80.35b
FPG (mmol/L) 5.50.6 7.21.5a 6.10.6 5.70.3b
FPI (pmol/L) 200246 266233 382164 18372b
HOMA-IR 7.00.9 12.32.2a 14.90.6 6.70.1
Triglycerides (mmol/L) 2.01.1 2.481.3a 2.30.5 1.750.3b
HDL-cholesterol (mmol/L) 1.240.3 1.150.3 0.910.18 1.230.2b
hsCrP (mg/L) 0.851.2 1.10.9 4.360.7 2.760.7b
ap<0.05 for comparisons between NGT and T2D.
bp<0.05 for comparisons between 6 months post bariatric surgery and baseline.
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attributed to differences in food intake, locomotion or fuel
utilization (respiratory quotient, RQ; Supporting Information
Fig 9A–C).
To better elucidate the metabolic‐endocrine phenotype of
HFD‐fed FasDmye mice, hyperinsulinaemic‐euglycaemic clamp
studies were performed. A signiﬁcantly increased glucose
infusion rate in HFD‐fed FasDmye compared to FasF/F mice
was noted, consistent with improved whole‐body insulin
sensitivity (see Fig 3A and Supporting Information Fig 10A–C
for detailed time courses). Importantly, insulin‐stimulated
glucose disposal rate was higher in FasDmye compared to
FasF/F littermates suggesting improved skeletal muscle insulin
sensitivity (Saberi et al, 2009b; Fig 3B). Remarkably, such
protective effect against insulin resistance seemed to be speciﬁc
to skeletal muscle since insulin‐mediated inhibition of endoge-
nous (mainly reﬂecting hepatic) glucose production was not
different between FasF/F and FasDmye mice (Fig 3C) as was
insulin‐mediated decrease of circulating FFA levels (Supporting
Information Fig 11). Consistent with clamp studies, insulin‐
stimulated glucose uptake into isolated soleus muscle was
signiﬁcantly increased in HFD‐fed FasDmye compared to FasF/F
littermates (Fig 3D), corresponding to increased insulin‐induced
phosphorylation of Akt and AS160 in skeletal muscle of myeloid‐
speciﬁc Fas knockout mice (Fig 3E and F). In contrast,
no signiﬁcant differences in insulin‐stimulated Akt phosphoryl-
ation were observed in white adipose tissue or liver of high fat‐
fed FasDmye and FasF/F mice (Supporting Information Fig 12A
and B). Moreover, mRNA expression of cytokines and macro-
phage markers in adipose tissue and liver were comparable
in both groups suggesting that myeloid cell‐expressed Fas
does not have a major impact on adipose tissue and/or liver
inﬂammation (Supporting Information Fig 12C and D). In
addition, ﬂow cytometric analysis revealed similar immune cell
inﬁltration and macrophage polarization in adipose tissue and
Chow HFD
0
5
10
15
**
**
B
od
y 
w
ei
gh
t g
ai
n 
(g
)
D
0 30 60 90 120
0
5
10
15
20
25
***
*
FasΔmye Chow
FasΔmye HFD
FasF/F Chow
FasF/F HFD
Time (min)
B
lo
od
 g
lu
co
se
(m
m
ol
/l)
FE
0 15 30 45 60
4
6
8
10
*
*
Time (min)
B
lo
od
 g
lu
co
se
(m
m
ol
/l)
BA
Chow HFD
0
500
1000
1500
2000
2500 **
M
FI
 C
D
95
Monocytes
(GR1low/im MAC1+)
Monocytes
(GR1low/im MAC1+)
0 102 103 104 105
<PE-A>: CD95
0
20
40
60
80
100
%
 o
f M
ax
FasF/F
Fas∆mye
Fas-def
C
Neutrophils
(GR1hi MAC1+)
FasF/F
Fas∆mye
Fas-def
0
20
40
60
80
100
%
 o
f M
ax
0 102 103 104 105
<PE-A>: CD95
Figure 2. FasDmye mice are protected from HFD‐induced glucose intolerance.
A. Flow cytometric analysis of peripheral blood leukocytes of chow- and HFD-fed mice. Monocytes (GR1low/im MAC1þ) were stained with respective
antibodies. Bar graphs show mean fluorescence intensity (MFI) of Fas (CD95) of live monocytes. n¼6–8, p¼0.005 (Student’s t-test). Error bars represent
SEM.
B,C. Flow cytometric analysis of circulating monocytes (B) and neutrophils (C) of Fas-deficient, FasF/F and FasDmye mice. Cells were stained with respective
antibodies and Fas fluorescence was measured.
D. Body weight change during 6 weeks of chow- or HFD-fed in FasF/F and FasDmye mice. n¼7–20. p¼0.002 (FasF/F chow vs. HFD); p¼0.001 (FasDmye chow
vs. HFD; Student’s t-test). Error bars represent SEM.
E. Intra-peritoneal glucose-tolerance test in chow- and HFD-fed FasF/F and FasDmye mice at 12 weeks of age. n¼6–10. p¼0.049 and 0.035 after 15 and
60min, respectively; p¼0.008 (ANOVA). All error bars represent SEM.
F. Intra-peritoneal insulin-tolerance test in chow- and HFD-fed FasF/F and FasDmye mice at 12 weeks of age. n¼6–10. p¼0.034 (15min), p¼0.012 (30 min;
ANOVA). All error bars represent SEM.
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livers of HFD‐fed control and myeloid‐speciﬁc Fas knockout
mice (Supporting Information Fig 12E–G).
To further characterize skeletal muscle from FasDmye mice,
mRNA expression of cytokines as well as markers of b‐oxidation
and lipogenesis were measured, and were found to be expressed
at similar levels in HFD‐fed knockout and control mice
(Supporting Information Fig 13). Importantly, there was neither
a difference in inﬂammatory cell marker expression nor in
immune cell inﬁltration and macrophage polarization in skeletal
muscle between FasF/F and FasDmye littermates as determined by
real‐time RT‐PCR and ﬂow cytometry (Supporting Information
Fig 13A and 13B). Moreover, HFD did not induce Fas expression
in skeletal muscle of C57BL6/J mice (Fig 3G) and Fas protein
levels could neither be detected in skeletal muscle of HFD‐fed
FasF/F nor FasDmye mice, conﬁrming previous ﬁndings (Wueest
et al, 2010b). Hence, improved skeletal muscle insulin sensitivity
in myeloid‐speciﬁc Fas knockout mice is likely driven by an
endocrine process, rather than a paracrine effect within
skeletal muscle itself.
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Figure 3. FasDmye mice are protected from HFD‐induced muscle insulin resistance.
A–C. Glucose infusion rate (GIR), insulin-stimulated glucose disposal rate (IS GDR) and % suppression of endogenous glucose production (EGP) during
hyperinsulinaemic-euglycaemic clamps, n¼4–5, p¼0.026 (A) and p¼0.018 (B; Student’s t-test). Error bars represent SEM.
D. Insulin-stimulated glucose uptake into isolated soleus muscle of HFD-fed FasF/F and FasDmye mice relative to basal uptake. n¼4–6, p¼0.039 (Student’s
t-test). Error bars represent SEM.
E,F. Representative Western blots of total muscle lysates of FasF/F and FasDmye mice. Graphs show results of 6–10 (E) and 7–8 (F) mice. p¼0.036 (E) and
p¼0.031 (F) (Student’s t-test). Error bars represent SEM.
G. mRNA expression of respective genes in skeletal muscle of chow (white bars) and HFD-fed (black bars) mice. n¼4. p¼0.002 (Student’s t-test). Error bars
represent SEM.
Table 2. Phenotypic characteristics of HFD‐fed FasF/F and FasDmye mice
FasF/F FasDmye
Body weight (g) 28.80.8 28.20.7
Blood glucose (mmol/L) 9.50.5 8.30.3
Insulin (pmol/L) 146.619.9 120.531.4
FFA (mmol/L) 0.770.09 0.770.08
TG (mg/dl) 117.729.7 106.913.9
Adiponectin (mg/ml) 41.46.1 31.14.6
Leptin (pg/ml) 48.111.5 44.79.8
IL-6 (pg/ml) 4.10.7 2.61.3
MCP-1 (pg/ml) 6.80.8 6.40.5
IL-10 (pg/ml) n.d. n.d.
LPS (EU/ml) 8.61.1 8.31.2
n.d.¼ not detectable.
Mice were fasted for 8 h. Results are the means SEM of 5–15 mice.
p¼0.049 (Student’s t-test).
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To further conﬁrm the causal role of myeloid Fas in obesity‐
associated skeletal muscle insulin resistance, we generated
mice deﬁcient of Fas in all haematopoietic‐derived cells using
adoptive bone marrow (BM) transfer. Wild‐type C57BL6/J mice
receiving a BM transplant from total body Fas‐deﬁcient (BM
Fas‐def) mice showed a marked reduction in Fas protein
content in myeloid cells compared to BM WT mice (Supporting
Information Fig 14). Conﬁrming our results from myeloid‐
speciﬁc Fas knockout mice generated with the cre‐lox technique,
BM Fas‐def chimeras were protected from HFD‐induced skeletal
muscle insulin resistance (Supporting Information Fig 15).
Phenotypic characteristics of these mice are reported in
Supporting Information Table S1.
Fas depletion in haematopoietic cells of ob/ob mice improves
skeletal muscle insulin sensitivity
To further unravel a potential role of myeloid‐expressed Fas in
modulating skeletal muscle insulin resistance and to rule out
any speciﬁc effects of the HFD, Fas was depleted in myeloid/
haematopoietic cells of the leptin‐deﬁcient (ob/ob) mouse using
adoptive BM transfer. Eight weeks after transplantation, glucose
tolerance was improved in chimeric Fas‐def ob/obmice (Fig 4A).
Moreover, glucose infusion rate (GIR) during hyperinsulin-
aemic‐euglycaemic clamp studies was higher in Fas‐def ob/ob
compared to WT ob/obmice (see Fig 4B for steady‐state glucose
infusion rates and Supporting Information Fig 16 for detailed
time courses). Importantly, observed differences in GIR between
the two groups were not due to differences in hepatic insulin
sensitivity (Fig 4C), but rather to signiﬁcantly improved skeletal
muscle insulin sensitivity in Fas‐def ob/ob mice (Fig 4D).
Jointly, these results suggest that depletion of Fas in
myeloid/haematopoietic cells as demonstrated either by line-
age‐speciﬁc elimination or by total BM transplantation protects
mice from obesity‐induced skeletal muscle insulin resistance,
without affecting hepatic or adipose tissue insulin sensitivity
or HFD‐induced weight gain.
Fas mediates myeloid‐muscle cell communication leading to
myocellular insulin resistance
Lipopolysaccharides (LPS) injections were previously shown to
induce insulin resistance in mice (Arkan et al, 2005; Ling
et al, 1994). In such treated animals, inﬂammation is mimicked
in the absence of chronic caloric surplus and tissue inﬁltration
with inﬂammatory cells. Moreover, the relevance of such
approach is further strengthened by the ﬁnding that plasma LPS
levels are elevated in HFD‐fed mice due to increased absorption
of LPS from the gut and, thus, LPS was postulated to initiate
obesity and insulin resistance (Cani et al, 2007; Ley et al, 2006).
In order to explore the notion whether myeloid cell‐speciﬁc Fas
deletion protects against LPS‐induced insulin resistance, LPS
was injected intraperitoneally (1mg/kg body weight). As
depicted in Fig 5A, glucose tolerance was impaired in FasF/F
mice, whereas FasDmye littermates were partly protected from
LPS‐induced deterioration of glucose metabolism. Of note,
insulin levels after LPS injection were similar in both groups
(FasF/F 131.6 22.6 pmol/L vs. FasDmye 138.0 18.9 pmol/L).
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LPS was previously demonstrated to increase circulating
TNFa and IL‐6 levels in mice (McIlwain et al, 2012). Moreover,
interruption of Fas–FasL signalling suppressed cytokine expres-
sion induced by LPS in mouse macrophages (Ma et al, 2004). As
shown in Fig 5B, LPS‐stimulated mRNA expression of TNFa but
not IL‐6 (data not depicted: 1.0 0.28 vs. 0.74 0.28; p¼ 0.51)
was signiﬁcantly reduced in circulating immune cells isolated
from FasDmye mice. Moreover, LPS‐induced circulating TNFa
levels were signiﬁcantly lower in FasDmye compared to FasF/F
mice (Fig 5C). Similar to ﬁndings presented in mice, LPS
increased Fas expression in RAW 264.7 cells (a murine myeloid
cell line), an effect that was greatly blunted after siRNA‐
mediated depletion of Fas expression (Fig 5D). Concomitantly,
Fas down‐regulation in RAW cells signiﬁcantly decreased LPS‐
induced release of TNFa into culture medium (Fig 5E),
suggesting a role for Fas in LPS‐induced TNFa secretion. In
contrast to Fas, its ligand (FasL) is not induced in RAW cells after
LPS stimulation (Supporting Information Fig 17).
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To investigate a potential role of Fas in mediating myeloid‐
muscle inter‐cellular communication, the effect of conditioned
medium harvested from RAW cells was tested on insulin
signalling and metabolism in L6 myotubes, mature 3T3‐L1
adipocytes or HepG2 hepatocytes. Conditioned medium from
RAW cells over‐expressing Fas (in response to LPS stimulation)
decreased insulin‐stimulated glucose uptake into L6 myotubes
(Fig 5F), potentially recapitulating the link between obesity‐
induced monocyte Fas over‐expression and muscular insulin
resistance (Fig 1). Fas’ causal role in the process was supported
by demonstrating a reversal of this effect when Fas‐depleted
RAW cells were used (Fig 5F). To unravel a possible role for
reduced LPS‐stimulated TNFa release from Fas‐depleted RAW
cells, insulin‐stimulated glucose uptake into L6 myotubes was
performed in the presence of neutralizing TNFa antibody. The
inhibitory effect of LPS‐treated RAW cell media on insulin‐
stimulated glucose uptake was blunted after TNFa neutraliza-
tion (Fig 5G) suggesting a TNFa‐dependent effect of conditioned
media on insulin resistance. Importantly, Fas‐depletion in
myeloid cells had no protective effect on conditioned media‐
induced insulin resistance in mature 3T3‐L1 adipocytes (Fig 5H)
or in HepG2 hepatocytes (Supporting Information Fig 18).
To further unravel a causative role for TNFa in mediating
obesity‐induced myeloid Fas‐dependent muscle insulin resis-
tance, its expression and plasma levels were analysed. As shown
in Fig 6A, TNFa expression was signiﬁcantly reduced in
circulating immune cells isolated from HFD‐fed FasDmye
compared to FasF/F mice. Moreover, circulating TNFa concen-
trations were signiﬁcantly reduced in HFD‐fed FasDmye mice
(Fig 6B), while plasma IL‐6 levels where not different. Of note,
plasma LPS levels were similar in both genotypes (Table 2).
Likewise, circulating TNFa levels were signiﬁcantly lower in
HFD‐fed BM Fas‐defmice (Supporting Information Table S1) and
reduced in Fas‐def ob/ob mice (4.5 0.5 pg/ml in Fas‐def ob/ob
vs. 5.6 0.9 pg/ml in WT ob/ob). Moreover, treatment of HFD‐
fed FasF/F and FasDmye littermates with the TNFa blocking
monoclonal antibody inﬂiximab (Araujo et al, 2007), which
recognizes both human as well as mouse TNFa epitopes (Qiu
et al, 2011) abolished HFD‐induced differences in glucose
tolerance between both groups (Fig 6C) supporting the notion
that circulating TNFa, induced by monocytic Fas, contributes to
HFD‐induced glucose intolerance.
Human monocyte Fas expression correlates positively with
serum LPS and TNFa
In order to evaluate a potential involvement of TNFa in
mediating the effect of monocyte‐speciﬁc Fas on skeletal muscle
insulin resistance, we determined circulating TNFa and LPS
levels in the obese human cohort. Monocyte Fas mRNA
positively correlated with circulating LPS (Fig 7A) and TNFa
levels (Fig 7B). Multivariate linear regression models revealed
that the correlations of monocytic Fas expression with LPS and
TNFa serum concentrations are independent of age, gender and
BMI (Supporting Information Table S2). In addition, weight loss
in obese patients 6 months after bariatric surgery was associated
with reduced circulating LPS and TNFa levels (Fig 7C and D) and
BMI‐adjusted changes in monocyte Fas expression signiﬁcantly
correlate with changes in circulating LPS (r¼ 0.14, p¼ 0.045)
and TNFa (r¼ 0.15, p¼ 0.04). Jointly, these data support a role
for monocyte‐expressed Fas in the development of obesity‐
associated (muscle) insulin resistance in humans potentially via
increased release of TNFa into circulation.
DISCUSSION
Unraveling inter‐organ and inter‐cell type speciﬁc crosstalk
pathways underlying obesity‐associated insulin resistance not
only enhances our understanding of this complex disease
process, but can yield new pharmaceutical interventions. The
“inﬂammatory basis of obesity‐associated morbidity” encom-
passes a particular challenge, since it involves activation of
inﬂammatory cascades in multiple haematopoietic and non‐
haematopoietic cell types, and includes systemic and local
markers of low‐grade and chronic inﬂammatory activation that
are all tightly inter‐connected. The present study revealed a
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pathway in which myeloid cell‐expressed Fas regulates
systemic levels of TNFa. The latter in turn determines whole‐
body insulin sensitivity, particularly by modulating skeletal
muscle insulin responsiveness. The major ﬁndings of this study
supporting this proposition are: (i) myeloid cell‐speciﬁc Fas
disruption in mice results in lower circulating levels of TNFa,
with improved whole‐body insulin sensitivity that can be largely
assigned to skeletal muscle; (ii) in obese human subjects,
monocyte Fas expression correlates with circulating levels of
TNFa and with glucose disposal rate. Demonstrating the
protective effect of myeloid Fas ablation on skeletal muscle
insulin sensitivity in the context of diet‐induced obesity and
leptin‐deﬁciency as well as in response to LPS suggests the
possibility that myeloid Fas is not an initiator of inﬂammation in
obesity, but rather an ‘intermediate integrator’ that may respond
to inﬂammatory cues like increased plasma LPS levels in the
obese state. Thus, the myeloid cell—muscular crosstalk
unraveled here is likely merely a segment of a more intricate
pathway, in which myeloid Fas may constitute a critical
node.
A speciﬁc example for the regulatory role of Fas is exempliﬁed
by the response to LPS. LPS was previously found to induce
inﬂammatory cytokines in monocytes and macrophages, and
interruption of Fas–FasL signalling suppressed nuclear factor‐kB
activation and cytokine expression induced by LPS in primary
human and mouse macrophages (Ma et al, 2004). Complemen-
tarily, Fas activation induced a rapid release of pro‐inﬂammatory
cytokines in macrophages (Wang et al, 2010) and human
monocytes (Park et al, 2003), which was dependent on toll‐like
receptor 4 (TLR4), a major receptor of LPS. We show here that
LPS‐induced up‐regulation of Fas protein levels in myeloid cells
signiﬁcantly contributes to TNFa release. In vivo, high fat dieting
(possibly via increased circulating LPS levels) increases myeloid
Fas protein expression, and myeloid‐speciﬁc Fas knockout
reduces HFD‐ and LPS‐induced circulating TNFa but not IL‐6
levels. Hence, our data suggest that myeloid‐cell expressed Fas
plays an important role in the regulation of circulating TNFa
levels. Moreover, our data provide evidence for a similar role of
monocytic Fas in humans: monocyte Fas expression in obese
people correlated with circulating LPS as well as TNFa
concentrations and the drop in LPS levels in patients after
bariatric surgery was paralleled by reduced monocytic Fas and
circulating TNFa levels as well as improved insulin sensitivity.
As previously reported, the composition of gut microbiota
changes after bariatric surgery (Clement, 2011; Furet et al, 2010)
and, thus, the observed improvement of glucose metabolism
may at least in part be due to reduced endotoxemia and
consequently reduced LPS levels (Manco et al, 2010). A role for
Fas in metabolic diseases in human is further supported by a
recent study revealing an association of Fas and FasL gene
promoter polymorphisms with type 2 diabetes (Nolsoe
et al, 2006).
TNFa has been among the ﬁrst inﬂammatory mediators to be
implicated in the induction of insulin resistance in obesity
(Hotamisligil et al, 1993). While TNFa infusion in healthy
humans had no effect on endogenous glucose production, it
induced skeletal muscle insulin resistance via inhibition of Akt
substrate 160 phosphorylation (Plomgaard et al, 2005). Similar-
ly, we found here that the decrease in circulating TNFa levels in
mice with myeloid‐speciﬁc deletion of Fas was associated with
improved skeletal muscle but not liver insulin sensitivity.
Moreover, neutralization of TNFa blunted HFD‐induced differ-
ences in glucose tolerance between myeloid‐speciﬁc Fas
knockout and control mice, further supporting a causative role
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for TNFa in the observed phenotype. Furthermore, monocytic
Fas expression in obese human individuals correlated positively
with circulating TNFa concentration suggesting that the latter
might be one of the downstream effectors of Fas up‐regulation in
myeloid cells in obesity‐induced insulin resistance in human
individuals. Of note, TNFa neutralization was reported to
improve insulin resistance in diabetic patients with rheumatoid
arthritis or Crohn’s disease who were also receiving anti‐TNFa
treatment (inﬂiximab) for their autoimmune disease (Gupta‐
Ganguli et al, 2011). Since we found no signiﬁcant difference in
immune cell inﬁltration and local cytokine expression in fat, liver
and skeletal muscle between HFD‐fed FasF/F and FasDmye
littermates, Fas expression in monocytes does not seem to
impact onmonocyte migration into peripheral tissue, supporting
the idea that monocyte recruitment is mainly guided by recipient
tissue rather than properties of circulating monocytes (Oh
et al, 2012). Moreover, our ﬁndings would also suggest that
myeloid cells rather than adipose tissue are the main source for
circulating TNFa. Of note, the chosen period of high fat feeding
(6 weeks) in our study is rather short. We cannot exclude that
longer exposure to HFD may have led to a higher degree of
adipose tissue inﬂammation and hepatic steatosis (Strissel
et al, 2007), and, hence, myeloid‐speciﬁc Fas deletion may have
also inﬂuenced adipose tissue inﬂammation and/or hepatic
insulin resistance.
The effect of LPS on cytokine expression is mainly mediated
via TLR4, a pattern‐recognition receptor known to regulate
release of pro‐inﬂammatory cytokines such as TNFa and IL‐6
from monocytes/macrophages (Nguyen et al, 2007; Shi
et al, 2006). As mentioned above, Fas was previously shown
to modulate/enhance TLR4‐mediated cytokine production
(Ma et al, 2004). Hence, the beneﬁcial effect of myeloid‐speciﬁc
Fas depletion on glucose tolerancemay bemerely due to reduced
TLR4‐signalling. However, myeloid/haematopoietic cell‐speciﬁc
TLR4 knockout mice as generated by adoptive BM transfer were
not protected from HFD‐induced skeletal muscle insulin
resistance, whereas hepatic insulin sensitivity was signiﬁcantly
improved (Supporting Information Fig 19). Our data are in
agreement with a previous study revealing blunted HFD‐induced
adipose and liver inﬂammation and ameliorated obesity‐induced
adipose and liver insulin resistance but no improvement in
skeletal muscle insulin sensitivity in mice with haematopoietic
cell‐speciﬁc deletion of TLR4 (Saberi et al, 2009b). However, in
contrast to this study (Saberi et al, 2009b), we found no
difference in GIR between chimeras (Supporting Information
Fig 19), which might be explained by different periods of HFD
(6 weeks vs. 16 weeks). Of note, TNFa levels in HFD‐fed
haematopoietic cell‐speciﬁc TLR4KO mice were comparable to
wild‐type chimeras (2.70 0.29 pg/ml vs. 2.49 0.3.5 pg/ml;
p¼ 0.63).
In conclusion, our results reveal an important and unique role
for myeloid cell expressed Fas in mediating obesity‐induced
insulin resistance in skeletal muscle. Pharmaceutical inhibition
of Fas or its signalling pathway in myeloid cells may emerge as a
promising new avenue in the treatment of insulin resistance and
therefore type 2 diabetes.
MATERIALS AND METHODS
Human samples
A total of 246 Caucasian men (n¼118) and women (n¼128) were
selected among 1500 subjects recruited in the context of a study on
insulin resistance at the Department of Medicine, University of Leipzig
to represent a wide range of obesity, insulin sensitivity, and glucose
tolerance. The age ranged from 19 to 80 years and BMI from 17.1 to
79.1 kg/m2. Subjects were subsequently divided into groups of NGTand
type 2 diabetes (T2D) according to ADA‐criteria (Anonymous, 2011). All
study protocols have been approved by the ethics committee of the
University of Leipzig. All participants gave written informed consent
before taking part in the study.
Bariatric surgery study
Fourteen Caucasian obese volunteers (10 females, 4 males) partici-
pated in a prospective weight loss study before and 6 months after
gastric sleeve resection. The baseline BMI was 548 kg/m2 and the
BMI 6 months after bariatric surgery was 36.37.3 kg/m2. Individuals
fulﬁlled the following inclusion criteria: (i) absence of any acute or
chronic inﬂammatory disease as determined by a leukocyte count
>7000Gpt/L, C‐reactive protein (CRP) >5.0mg/dl or clinical signs of
infection, (ii) undetectable antibodies against glutamic acid decarbox-
ylase (GAD), (iii) no clinical evidence of either cardiovascular or
peripheral artery disease, (iv) No thyroid dysfunction, (v) no alcohol or
drug abuse, (vi) no pregnancy. BMI was calculated as weight divided by
squared height. Hip circumference was measured over the buttocks;
waist circumference was measured at the midpoint between the lower
ribs and iliac crest.
Fas/FasL mRNA expression studies
Human monocytes were obtained from heparinized blood. Monocytes
were separated using superparamagnetic polystyrene beads coated
with a primary monoclonal antibody speciﬁc for the CD14 membrane
antigen expressed on human monocytes (Invitrogen, Groningen,
Germany) and resuspended in Hanks balanced solution containing
(in mmol/L) NaCl 136, KCl 5.40, CaCl2 1, KH2PO4 0.44, Na2HPO4 0.34,
HEPES 10, pH 7.4. Total RNA was isolated from monocytes using the
RNeasy mini kit including RNase‐free DNase set (Qiagen, Hilden,
Germany). Using the transcriptor ﬁrst‐strand cDNA synthesis kit (Roche
Diagnostics, Mannheim, Germany), cDNA was synthesized from 2mg of
total RNA using oligo dT (12–18). Human Fas and FasL mRNA
expression, determined by a premixed assay on demand (PE
Biosystems, Darmstadt, Germany) was calculated relative to the mRNA
expression of HPRT (PE Biosystems). The speciﬁcity of the PCR was
veriﬁed by subjecting the ampliﬁcation products to agarose gel
electrophoresis.
Analysis of LPS, IL-6 and TNFa serum concentrations in human
cohorts
All baseline blood samples were collected between 8 and 10 am after
an overnight fast. Serum IL‐6 and TNFa concentrations were measured
by highly sensitive ELISAs for IL‐6 (Quantikine IL‐6, R&D Systems,
Oxford, UK) and TNFa (Alpco Diagnostics, Salem, NH, USA). Serum LPS
concentration was measured using a LAL Chromogenic Endpoint Assay
(Hycult Biotech Inc., PB Uden, The Netherlands).
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Animals
Total body Fas‐deﬁcient (Fas‐def) mice on C57BL/6J inbred strain
background (B6.MRLFaslpr) were obtained from The Jackson Laboratory.
C57BL/6J mice with exon IX of Fas ﬂanked with LoxP sites were
produced as described (Stranges et al, 2007) and crossed to
LysozymeM (LysM)‐Cre mice (B6,129‐Lys<tm1(Cre)Ifo>) to generate
myeloid‐speciﬁc deletions (FasDmye). All mice were housed in a speciﬁc
pathogen‐free environment on a 12‐h light‐dark cycle and fed ad
libitum with regular chow diet (Provimi Kliba) or HFD (58 kcal% fat w/
sucrose Surwit Diet, D12331, Research Diets). All protocols conformed
to the Swiss animal protection laws and were approved by the
Cantonal Veterinary Ofﬁce in Zurich, Switzerland.
Genotyping of animals
All mice were genotyped by PCR with primers amplifying the Cre
transgene (generating 350bp wild‐type and 700bp Cre allele
products) and Fas (generating 319bp wild‐type and 399bp ‘ﬂoxed’
allele products).
Bone marrow transfer
BM chimeras were generated by either transplanting 2106 B6.
MRLFaslpr/J CD45.2 (FAS‐KO), Tlr4tm1Aki (CD45.2) or C57BL/6J CD45.2
(control) total BM cells into lethally irradiated (2450 cGy) 6‐week‐
old B6.SJL CD45.1 or 6‐week‐old B6.V‐Lepob/OlaHsd recipient mice.
Recipient mice were maintained and bled at week 6 to check the
chimerism in peripheral blood and a >90% donor chimerism was
conﬁrmed in peripheral blood of all recipient animals.
Metabolic cage analysis
Locomotion, food and water intake, O2 consumption and CO2
production were determined for single housed mice during a 24‐h
period in a metabolic and behavioural monitoring system (Pheno-
Master, TSE Systems, Bad Homburg, Germany).
Intra-peritoneal glucose and insulin tolerance tests
For the intraperitoneal glucose tolerance test (ipGTT) mice were either
fasted for 5 h (ob/ob mice) or overnight (C57BL/6J), for the
intraperitoneal insulin tolerance tests (ipITT) mice were fasted for
3 h. Either glucose (0.25 g/kg body weight for ob/ob mice; 2 g/kg body
weight for C57BL/6J) or human recombinant insulin (0.75U/kg body
weight) were injected intraperitoneally (Konrad et al, 2007).
Glucose clamp studies
Glucose clamp studies were performed as described (Rytka et al, 2011).
Clamps were performed in freely moving mice. Glucose infusion rate
was calculated once glucose infusion reached a more or less constant
rate with blood glucose levels at 5mmol/L (80–90min after the start of
insulin infusion). Thereafter, blood glucose was kept constant at
5mmol/L for 20min and glucose infusion rate was calculated. The
glucose disposal rate was calculated by dividing the rate of [3‐3H]
glucose infusion by the plasma [3‐3H]glucose speciﬁc activity (Fisher &
Kahn, 2003; Kim et al, 2000). Endogenous glucose production during
the clampwas calculated by subtracting the glucose infusion rate from
the glucose disposal rate (Fisher & Kahn, 2003; Kim et al, 2000).
Insulin‐stimulated glucose disposal rate was calculated by subtracting
basal endogenous glucose production (equal to basal glucose disposal
rate) from glucose disposal rate during the clamp (Saberi et al, 2009a).
Glucose incorporation into isolated soleus muscle
Intact soleus muscle was isolated and thereafter incubated with or
without 2mU of insulin per ml. 2‐Deoxyglucose uptake was then
measured for 20min as described previously (Rudich et al, 2003).
Determination of plasma insulin, adipokines, free fatty acid and
triglyceride levels
Plasma insulin and FFA levels were determined as described (Konrad
et al, 2007). Plasma leptin and cytokine levels were determined with
mouse procarta cytokine assay kit (Affymetrix). Plasma adiponectin
levels were measured with an ELISA kit (Axxora). TG concentrations
were determined using a colorimetric assay (Sigma).
TNFa neutralization
Mice were treated with inﬂiximab (Remicade®, MSD) for 8 days by daily
injections (i.p.) of 50mg inﬂiximab dissolved in 100ml saline.
Stromal vascular fraction (SVF), muscle and liver cell isolation for
flow cytometry
After digestion of adipose tissue (Rudich et al, 2003), isolated cells were
centrifuged at 4°C (500 g) for 5min. SVF (pellet) was kept on ice in KRP
0.1% BSA. Centrifugation step was repeated with infra‐ and
supernatant for three times and obtained SVFs were pooled and
dissolved in PBS 0.1% BSA. For isolation of muscle cells, skeletal muscle
was minced in PBS and kept on ice. After centrifugation, 5ml
collagenase solution (0.5ml 10 HBSS, 4.5ml H2O, 75mg BSA, 10mg
collagenase II (Life Technologies)) was added to the pellet and shaken in
a water bath at 37°C for 20min. Thereafter, cells were centrifuged
(80 g) and supernatant was poured into 15ml ice‐cold media (DMEM
low glucose, 10% FBS). Digestion of the pellet was repeated twice.
Subsequently, cells were ﬁltered through a cell restrainer (100mm),
centrifuged (350 g), resuspended in erythrocyte lysis buffer and ﬁlled
up with ice‐cold PBS to 25ml. After ﬁltering through a 40mm cell
restrainer, cell pellet was dissolved in PBS 0.1% BSA. For liver cell
isolation, livers were mashed between glass slides and cells were
suspended in FACS buffer. Cell suspension was layered on Ficoll and
centrifuged (400 g) for 30min at 18°C. Cells on top of Ficoll were
collected and washed in FACS buffer.
Flow cytometric analysis
For ﬂow cytometric analysis of isolated SVF, muscle and liver cells, cells
were blocked with Fc blocker (anti CD16/32 BD pharmingen) on ice for
15min. Thereafter, cells were stained on ice for 30min with the
following antibodies: CD206‐Alexa Fluor 488, CD11c‐PE Cy7 (both
from Biolegend), CD45.2‐PE, CD8‐PE‐Cy5, CD4‐APC (all from eBio-
science), F4/80‐Fluor 780 (Alexa). Cells were subsequently washed for
three times and resuspended in Hoechst buffer. For ﬂow cytometry
analysis of circulating blood cells, mice were bled and red blood cells
were lysed using ACK lysis buffer (150mM NH4Cl, 10mM KHCO3,
0.1mM EDTA). Cell debris was removed by ﬁltering the cell suspension
using a 70mm cell strainer (BD). Peripheral leukocytes were stained
using ﬂuorochrome conjugated antibodies as follows: Paciﬁc Blue‐
conjugated anti‐CD45.1 (clone A20; Biolegend), FITC‐conjugated anti‐
GR‐1 (clone RB6‐8C5; ebioscience.com), PE‐conjugated anti‐FAS
(CD95; clone Jo2; BD‐Pharmingen), PE‐Cy5‐conjugated anti‐CD45.2
(clone 104; ebioscience), APC‐conjugated anti‐CD11c (clone M1/70;
ebioscience), eFluor 780 conjugated anti‐CD11b (clone M1/70;
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ebioscience) and Hoechst 33342 2mg/ml to exclude dead cells.
Immunophenotypical analysis was performed on a BD FACS Canto II
Flow Cytometer.
Histology
Fat tissues were ﬁxed in 4% buffered formalin and embedded in
parafﬁn. Sections were cut and stained with haematoxylin and eosin.
For each fat pad of a mouse, at least 100 adipocytes were analysed
(ImageJ software; National Institutes of Health, Bethesda, MD).
RNA extraction and quantitative reverse transcription-PCR (RT-
PCR)
Total RNA was extracted and reverse transcribed as described
(Wueest et al, 2010b). The following primers were used: TNF‐a
Mm00443258_m1, IL‐6 Mm00446190_m1, IL‐1b Mm0043422/
8_m1, cd11b Mm00434455_m1, cd11c Mm00498698_m1, cd68
Mm03047343_m1, F4/80 Mm00802529_m1, MCP‐1 Mm00441242_
m1, IL‐1b Mm0043422/8_m1, IL‐10 Mm00439614_m1, FAS
Mm00662319_m1, ACC‐1 Mm01304289_m1, CPT‐1 Mm00550438_
m1, AOX Mm00443579_m1, PGC‐1a Mm01208835_m1, FasL
Mm00438864_m1 (Applied Biosystems).
Western blotting
Cells or tissues were lysed and Western blots were performed as
previously described (Wueest et al, 2010b). The following primary
antibodies were used: anti‐Fas (clone 7C10), anti‐phospho‐AS160
(Thr642) and anti‐actin (Millipore), anti‐phospho‐Akt (Thr308; Cell
Signaling).
Cell culture experiments
RAW 264.7 cells were grown in RPMI 1640, 1% penicillin/streptomycin
(p/s), 1% glutamine and 10% FCS. At 30–50% conﬂuence, cells were
treated with siRNA (target sequences: 50 GAACCATTATGCTGATAAA 30 , 50
AAAGCCGAATGTCGCAGAA 30 ; scrambled sequences: 50 GACACTAAACGT-
GAATTAT 30 , 50 GCAACAGGCGTCAAGAAAT 30) in a transfection mixture
containing Lipofectamin 2000 (Invitrogen) in RPMI (without FCS,
without p/s) according to themanufacturer’s instructions. L6myotubes
differentiation and glucose uptake were performed as described (Niu
et al, 2003). For TNFa neutralization, L6 myotubes were incubated
with nTNFa or IgG control antibody (R&D Systems). Glucose uptake in
mature 3T3‐L1 adipocytes was performed as described (Wueest
et al, 2010a). HepG2 cells were cultivated in DMEM supplementedwith
10% FCS.
Data analysis
Animal data
Data are presented as means SEM and were analysed by two‐tailed
Student’s t‐test, one sample t‐test or one‐way ANOVA with a Tukey
correction for multiple group comparisons. p Values <0.05 were
considered signiﬁcant.
Human cohort data
Data are shown as means SEM unless stated otherwise. Before
statistical analysis, non‐normally distributed parameters were loga-
rithmically transformed to approximate a normal distribution.
The following statistical tests were used: paired Student’s t‐test,
Chi‐square test, and Pearson’s simple correlation. Prediction models for
monocyte Fas mRNA expression based on age, gender, anthropometric
and clinical parameters were calculated by multivariate linear
regression analysis. p Values <0.05 were considered to be statistically
signiﬁcant. Statistical analysis was performed using SPSS version 12.0
(Chicago, IL).
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The paper explained
PROBLEM:
Low grade inflammation in adipose tissue and liver has been
shown to contribute to the development of obesity-associated
insulin resistance and type 2 diabetes. However, it is presently
unknown whether inflammatory cells play a role in the
pathogenesis of skeletal muscle insulin resistance.
RESULTS:
Herein we demonstrate that expression of Fas (CD95) in
circulating monocytes correlate with skeletal muscle insulin
resistance in a large cohort of obese human individuals. To test a
causal role of monocyte-expressed Fas in the development of
skeletal muscle insulin resistance, we generatedmice lacking Fas
in myeloid cells. Such mice were protected from the develop-
ment of obesity-induced skeletal muscle insulin resistance
whereas adipose tissue inflammation and hepatic insulin
resistance were unaltered. Mechanistically, we provide evidence
that activation of Fas in myeloid cells mediate the release of
TNFa inducing skeletal muscle insulin resistance. Accordingly,
monocyte Fas expression correlated with circulating TNFa levels
in humans.
IMPACT:
Our results demonstrate an unanticipated crosstalk between
myeloid cells and skeletal muscle in the development of
obesity-associated insulin resistance. Pharmaceutical
inhibition of Fas or its signalling pathway in myeloid cells may
emerge as a promising future strategy to prevent or treat type 2
diabetes.
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